Advertisement
A or BRKR or DHR
Which Stock Would AI Choose? Agilent Technologies (A) vs. Bruker Corporation (BRKR) vs. Danaher Corporation (DHR) Stock Comparison
Key Takeaways
- Agilent Technologies (A), Bruker Corporation (BRKR), and Danaher Corporation (DHR) operate in the life sciences and diagnostics sector, with overlapping exposure to research, analytical instruments, and healthcare applications.
- Recent market activity shows A trading near the lower end of its 52-week range amid mixed earnings reactions, while BRKR has posted modest year-to-date gains and DHR benefited from a first-quarter earnings beat and raised guidance.
- Business models differ in scale and diversification: DHR offers broad exposure across multiple segments, A focuses on analytical instruments and diagnostics, and BRKR specializes in scientific instrumentation with strong academic and industrial demand.
- Valuation sensitivity varies, with A appearing relatively compressed on recent price action compared to peers, while DHR maintains premium positioning supported by consistent cash flow and M&A (mergers and acquisitions) history.
- Sector sentiment remains influenced by broader healthcare funding trends, China market recovery signals, and tariff concerns, creating differentiated momentum across the three names in recent weeks.
- Relative performance highlights trade-offs between stability (BRKR), scale-driven resilience (DHR), and potential rebound dynamics (A) in a mixed macro environment.
Introduction
Agilent Technologies (A), Bruker Corporation (BRKR), and Danaher Corporation (DHR) represent established players in the life sciences tools and diagnostics space. Investors and traders often compare these stocks to assess relative positioning within healthcare technology amid evolving research spending, regulatory shifts, and global supply dynamics. This analysis appeals to those seeking exposure to analytical instruments, biotechnology support, and diversified diagnostics, providing a framework for evaluating performance differentials, sector catalysts, and risk profiles in the current market environment.
A Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, diagnostics, and life sciences solutions serving pharmaceutical, academic, and environmental markets. In recent weeks, the stock has traded in a compressed range near the lower portion of its 52-week band, reflecting mixed first-quarter fiscal 2026 results that included revenue growth but some earnings per share (EPS) softness alongside a raised full-year outlook. Sentiment has been shaped by tariff and funding concerns alongside positive signals from new product launches and contract wins, contributing to cautious positioning ahead of the next earnings release.
BRKR Overview and Recent Performance
Bruker Corporation (BRKR) develops scientific instruments and solutions for life sciences, materials research, and industrial applications. Recent market activity has shown relative stability, with the shares posting modest year-to-date advances amid steady demand in academic and industrial segments. First-quarter updates highlighted ongoing execution, while broader performance metrics reflect resilience compared with some sector peers, supported by consistent instrumentation sales and limited volatility in recent weeks.
DHR Overview and Recent Performance
Danaher Corporation (DHR) operates a diversified portfolio spanning life sciences, diagnostics, and biotechnology platforms. In recent weeks, the stock reacted positively to first-quarter results that beat EPS expectations and prompted an upward revision to full-year guidance, despite modest revenue softness in certain areas. Performance has benefited from momentum in biotechnology applications and operational discipline, positioning the shares with greater relative stability amid sector-wide funding and macro considerations.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top-performing AI trading bots from a library of hundreds that execute strategies across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions, risk-adjusted returns, and consistency earn placement in this section. Available bots span a wide range of performance metrics, including varying win rates, profit factors, maximum drawdowns, and holding periods, allowing users to match strategies to different timeframes and ticker sets. This resource provides traders with transparent statistics to evaluate automated approaches suited to individual risk tolerance and market views.
Head-to-Head Comparison
Business models contrast in scope: DHR leverages a multi-platform approach with significant scale and historical M&A (mergers and acquisitions) activity, while A centers on precision analytical tools and BRKR emphasizes specialized instrumentation with academic and applied research exposure. Growth drivers include instrumentation demand for A and BRKR versus DHR’s broader biotechnology and diagnostics tailwinds. Recent momentum favors DHR following its earnings beat, with BRKR showing steadier price behavior and A exhibiting greater compression. Risk factors encompass macro funding sensitivity for all three, though DHR’s diversification may offer relative insulation. Sector exposure remains concentrated in healthcare technology, where valuation multiples respond to earnings visibility and China-related demand signals. Market sentiment reflects differentiated reactions to the same macro variables, creating trade-offs between scale advantages and niche positioning.
Tickeron AI Verdict
Based on observable trend consistency, earnings stability, and relative positioning in recent market activity, Tickeron’s AI would currently assign a probabilistic preference toward DHR, citing its earnings beat and guidance raise as supportive factors alongside broader diversification. A and BRKR present compelling attributes in instrumentation demand and valuation compression, respectively, though with more variable near-term signals. This assessment reflects data-driven pattern recognition rather than definitive forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileBRKR’s FA Score has 1 green FA rating(s), and DHR’s FA Score reflects 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- BRKR’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while BRKR’s TA Score has 4 bullish TA indicator(s), and DHR’s TA Score reflects 5 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 5 bearish.
- BRKR’s TA Score: 4 bullish, 5 bearish.
- DHR’s TA Score: 5 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -1.30% price change this week, while BRKR (@Medical/Nursing Services) price change was -1.15% , and DHR (@Medical Specialties) price fluctuated -1.31% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +7.70%. For the same industry, the average monthly price growth was +8.34%, and the average quarterly price growth was +1.99%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +14.19%. For the same industry, the average monthly price growth was +10.26%, and the average quarterly price growth was -6.43%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
BRKR is expected to report earnings on Aug 05, 2026.
DHR is expected to report earnings on Jul 21, 2026.
Industries' Descriptions
@Medical Specialties (+7.70% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+14.19% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| A | BRKR | DHR | |
| Capitalization | 35.8B | 8.39B | 127B |
| EBITDA | 1.96B | 306M | 7.08B |
| Gain YTD | -6.529 | 17.260 | -21.653 |
| P/E Ratio | 25.40 | 74.88 | 34.53 |
| Revenue | 7.23B | 3.46B | 24.8B |
| Total Cash | 1.81B | N/A | 5.7B |
| Total Debt | 3.36B | 1.67B | 18.5B |
A | BRKR | DHR | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 91 | 69 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 49 Fair valued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 44 | 92 | 80 | |
PRICE GROWTH RATING 1..100 | 48 | 38 | 60 | |
P/E GROWTH RATING 1..100 | 62 | 5 | 60 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 26 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is in the same range as DHR (10) in the Medical Specialties industry, and is somewhat better than the same rating for BRKR (49) in the Medical Specialties industry. This means that A's stock grew similarly to DHR’s and somewhat faster than BRKR’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DHR (100) in the Medical Specialties industry, and is in the same range as BRKR (100) in the Medical Specialties industry. This means that A's stock grew similarly to DHR’s and similarly to BRKR’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for DHR (80) in the Medical Specialties industry, and is somewhat better than the same rating for BRKR (92) in the Medical Specialties industry. This means that A's stock grew somewhat faster than DHR’s and somewhat faster than BRKR’s over the last 12 months.
BRKR's Price Growth Rating (38) in the Medical Specialties industry is in the same range as A (48) in the Biotechnology industry, and is in the same range as DHR (60) in the Medical Specialties industry. This means that BRKR's stock grew similarly to A’s and similarly to DHR’s over the last 12 months.
BRKR's P/E Growth Rating (5) in the Medical Specialties industry is somewhat better than the same rating for DHR (60) in the Medical Specialties industry, and is somewhat better than the same rating for A (62) in the Biotechnology industry. This means that BRKR's stock grew somewhat faster than DHR’s and somewhat faster than A’s over the last 12 months.
| A | BRKR | DHR | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 65% | 3 days ago 56% |
| Stochastic ODDS (%) | 2 days ago 54% | 2 days ago 72% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 59% | 2 days ago 72% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 68% | 2 days ago 59% | 2 days ago 67% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 72% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 73% | 2 days ago 54% |
| Advances ODDS (%) | 10 days ago 60% | 27 days ago 69% | 2 days ago 54% |
| Declines ODDS (%) | 8 days ago 62% | 2 days ago 72% | 7 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 72% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 59% | 2 days ago 51% |
Advertisement
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with A. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then A could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | -2.51% | ||
| A - BRKR | 78% Closely correlated | +0.14% | ||
| MTD - BRKR | 75% Closely correlated | -0.64% | ||
| WAT - BRKR | 68% Closely correlated | -0.29% | ||
| RVTY - BRKR | 68% Closely correlated | +0.87% | ||
| TMO - BRKR | 66% Loosely correlated | +1.15% | ||
More | ||||